KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Non Operating Income (2017 - 2025)

Teva Pharmaceutical Industries' Non Operating Income history spans 9 years, with the latest figure at -$220.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Income fell 0.92% year-over-year to -$220.0 million, compared with a TTM value of -$934.0 million through Dec 2025, up 4.79%, and an annual FY2025 reading of -$934.0 million, up 4.79% over the prior year.
  • Non Operating Income for Q4 2025 was -$220.0 million at Teva Pharmaceutical Industries, up from -$237.0 million in the prior quarter.
  • The five-year high for Non Operating Income was -$211.0 million in Q2 2022, with the low at -$290.0 million in Q1 2021.
  • Average Non Operating Income over 5 years is -$249.8 million, with a median of -$251.0 million recorded in 2022.
  • Year-over-year, Non Operating Income tumbled 105.98% in 2021 and then increased 22.99% in 2022.
  • Tracing TEVA's Non Operating Income over 5 years: stood at -$253.0 million in 2021, then increased by 3.16% to -$245.0 million in 2022, then decreased by 1.63% to -$249.0 million in 2023, then grew by 12.45% to -$218.0 million in 2024, then decreased by 0.92% to -$220.0 million in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Non Operating Income are -$220.0 million (Q4 2025), -$237.0 million (Q3 2025), and -$252.0 million (Q2 2025).